Concert Pharma (CNCE) Tops Q4 EPS by 8c

Concert Pharma (NASDAQ: CNCE) reported Q4 EPS of $0.03, $0.08 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $10.3 million versus the consensus estimate of $11.24 million.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c